Search

Displaying results 6391 - 6400 of 10000 in total
  1. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.

  2. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  3. Drug

    R411

    go.drugbank.com/drugs/DB05468
    Experimental

    It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.

  4. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    Integrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and migration. The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin ant...

  5. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  6. Drug

    Velaglucerase alfa

    go.drugbank.com/drugs/DB06720
    Approved

    Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.

  7. Drug

    Toyocamycin

    go.drugbank.com/drugs/DB13916
    Experimental

    It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.

  8. Drug

    Dichlorobenzene

    go.drugbank.com/drugs/DB14046
    ApprovedWithdrawn

    Dichlorobenzene refers to any of, or a mixture of, three isomers consisting of benzene in which two of the hydrogen atoms are replaced by chlorine atoms: ortho-, meta-, and paradichlorobenzene.

  9. Drug

    (S)-Warfarin

    go.drugbank.com/drugs/DB14055
    Investigational

    S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A7166]

  10. Drug

    Cemivameran

    go.drugbank.com/drugs/DB19415
    Approved

    It is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030]